Context Therapeutics Excited to Attend Major Investor Conferences
Context Therapeutics Inc. (NASDAQ: CNTX), a dedicated clinical-stage biopharmaceutical company, is making strides in oncology by developing T cell engaging bispecific antibodies aimed at tackling solid tumors. The company is set to make its presence known at several significant investor conferences, highlighting its continued commitment to advancing cancer therapies.
Upcoming Conference Schedule: Mark Your Calendars
As part of its investor outreach, Context Therapeutics has announced participation in the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Here are the details for these events:
Cantor Global Healthcare Conference
This event will take place on September 3, where a fireside chat is scheduled for 10:55 AM ET. In addition to the chat, Context will engage in one-on-one meetings throughout the day, providing a valuable opportunity for investors to connect with the management team.
H.C. Wainwright Annual Global Investment Conference
On September 8, at 3:30 PM ET, Context will also participate in a fireside chat. Following this discussion, the management team will hold one-on-one meetings for investors interested in deeper insights into the company's strategies and developments.
Ensuring Transparency and Communication
For those investors wishing to get more involved or to request meetings with the Context management team, they are encouraged to reach out through the appropriate conference representatives. Moreover, additional inquiries can be channeled through their investor relations email at IR@contexttherapeutics.com.
About Context Therapeutics: Innovating Cancer Treatment
Context Therapeutics is at the forefront of cancer biopharmaceuticals, focusing on the development of T cell engaging bispecific antibodies for solid tumors. Their portfolio includes promising candidates such as CTIM-76, a Claudin 6 x CD3 TCE, and CT-95, a Mesothelin x CD3 TCE, alongside CT-202 targeting Nectin-4. The company is committed to building a comprehensive and effective therapeutic range to combat various cancers.
Investor Relations Contact
For any further inquiries or information, investors can reach out to Jennifer Minai-Azary, the Chief Financial Officer of Context Therapeutics. She is available at the aforementioned email address, aiming to facilitate clearer communication and understanding between investors and the company.
Frequently Asked Questions
What are the main events Context Therapeutics is attending?
Context Therapeutics will participate in the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference.
When is the fireside chat at the Cantor Global Healthcare Conference?
The fireside chat at the Cantor Conference is scheduled for September 3 at 10:55 AM ET.
What strategy is Context Therapeutics pursuing in oncology?
Context is focused on developing T cell engaging bispecific antibodies to provide innovative treatments for solid tumors.
Who should investors contact for additional information?
Investors can contact Context Therapeutics' investor relations via email at IR@contexttherapeutics.com for further information and inquiries.
What types of therapeutics are included in Context's portfolio?
Context's portfolio includes several innovative T cell engaging bispecific antibodies like CTIM-76 and CT-95, targeting specific cancer-related proteins.
